Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...
Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a ...
The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.
Merck & Co. has won its first U.S. approval for use of its blockbuster cancer drug Keytruda in patients with malignant pleural mesothelioma, a rare cancer that grows in the membrane that lines the ...
Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...
Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on ...
Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy ...
The Food and Drug Administration (FDA) has approved Keytruda ® (pembrolizumab ... unresectable advanced or metastatic malignant pleural mesothelioma (MPM). The approval was supported by data ...
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback